Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19
Copyright © 2021 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 229(2021) vom: 15. Aug., Seite 108795 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2021
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Case Reports Journal Article Research Support, N.I.H., Extramural COVID-19 CaMK4 Complement activation Immune complexes Kidney injury MUC1 SARS-CoV-2 mehr... |
| Zusammenfassung: | Copyright © 2021 Elsevier Inc. All rights reserved. Acute and chronic kidney failure is common in hospitalized patients with COVID-19, yet the mechanism of injury and predisposing factors remain poorly understood. We investigated the role of complement activation by determining the levels of deposited complement components (C1q, C3, FH, C5b-9) and immunoglobulin along with the expression levels of the injury-associated molecules spleen tyrosine kinase (Syk), mucin-1 (MUC1) and calcium/calmodulin-dependent protein kinase IV (CaMK4) in the kidney tissues of people who succumbed to COVID-19. We report increased deposition of C1q, C3, C5b-9, total immunoglobulin, and high expression levels of Syk, MUC1 and CaMK4 in the kidneys of COVID-19 patients. Our study provides strong rationale for the expansion of trials involving the use of inhibitors of these molecules, in particular C1q, C3, Syk, MUC1 and CaMK4 to treat patients with COVID-19 |
|---|---|
| Beschreibung: | Date Completed 12.08.2021 Date Revised 19.08.2021 published: Print-Electronic CommentIn: Nat Rev Nephrol. 2021 Sep;17(9):572. doi: 10.1038/s41581-021-00469-5. - PMID 34312512 Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2021.108795 |